Expanding the around globe!
Pharming And Cytobioteck Announce Extension Of Distribution Agreement For Ruconest®
Print Friendly
Leiden, The Netherlands, 09 February 2016: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) announced today that it has extended the exclusive distribution agreement with Cytobioteck S.A.S. (“Cytobioteck”), a privately owned Bogota, Colombia based specialty healthcare company, for the distribution of RUCONEST® (recombinant, non-blood derived human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) by adding countries in Central and South America.
Pharming entered into the original exclusive distribution agreement with Cytobioteck in May 2015 for the distribution of RUCONEST® in Colombia and Venezuela. Under the extended agreement, Cytobioteck will also exclusively distribute RUCONEST® in Argentina, Costa Rica, the Dominican Republic and Panama. Cytobioteck will continue to drive all regulatory processes and purchase its commercial supplies of RUCONEST® from Pharming at a fixed transfer price.
Sijmen de Vries, Pharming’s CEO, commented: “We are very pleased that we have been able to extend the agreement with Cytobioteck for the distribution of RUCONEST® in Central and South America. Over the past year Cytobioteck have made good progress with the regulatory processes in Colombia and Venezuela and several emergency treatments have already been provided to HAE patients in these countries in accordance with local regulations.”
Cytobioteck’s CEO, Dr. Osvaldo Piñeros, commented: “We look forward to being able to provide HAE patients with RUCONEST® in Argentina, Costa Rica, the Dominican Republic and Panama, in addition to Colombia and Venezuela. Our role is to deliver the best therapies available for our patients and we believe RUCONEST® provides a significant treatment option for HAE patients as the one and only recombinant, non-blood derived C1-esterase inhibitor replacement therapy with a proven and consistent efficacy and safety profile.”
